Real-world experience with daclatasvir plus sofosbuvir +/- ribavirin for post-liver transplant HCV recurrence and severe liver disease

Author(s):
Herzer, K.; Welzel, T.M.; Spengler, U.; Hinrichsen, H.; Klinker, H.; Berg, T.; Ferenci, P.; Peck-Radosavljevic, M.; Inderson, A. (0000-0001-7644-0668); Zhao, Y.; Jimenez-Exposito, M.J.; Zeuzem, S.
Published
2017
Publication type
Article / Letter to editor
Decompensatedfibrosing cholestatic hepatitisHCV therapyliver transplant
Date issued
2017-03-31
Language
English
Is part of
Transplant International (2017), Vol. 30, no. 3, p. 243-255
hdl
1887/117283
doi
10.1111/tri.12910